Bryan Cox
Chief Tech/Sci/R&D Officer at TRISALUS LIFE SCIENCES, INC.
Net worth: 860 891 $ as of 2024-04-29
Profile
Dr. Bryan F.
Cox is a Chief Scientific & Manufacturing Officer at TriSalus Life Sciences, Inc. and a Chief Executive Officer at Nephraegis Therapeutics, Inc.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2024-02-11 | 86,696 ( 0.32% ) | 860 891 $ | 2024-04-29 |
Bryan Cox active positions
| Companies | Position | Start |
|---|---|---|
| TRISALUS LIFE SCIENCES, INC. | Chief Tech/Sci/R&D Officer | 2023-08-09 |
Nephraegis Therapeutics, Inc.
 Nephraegis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Nephraegis Therapeutics, Inc. is a biopharmaceutical company that focuses on developing a family of proprietary drug candidates to prevent and treat acute kidney injury (AKI). The company is based in Lake Forest, IL. The company's lead compound, NPH-022, is an epoxyeicosatrienoic-related compound (EET) with optimized pharmacokinetic properties. The CEO of the company is Bryan F. Cox. | Chief Executive Officer | - |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| TRISALUS LIFE SCIENCES, INC. | Health Technology |
| Private companies | 1 |
|---|---|
Nephraegis Therapeutics, Inc.
Nephraegis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Nephraegis Therapeutics, Inc. is a biopharmaceutical company that focuses on developing a family of proprietary drug candidates to prevent and treat acute kidney injury (AKI). The company is based in Lake Forest, IL. The company's lead compound, NPH-022, is an epoxyeicosatrienoic-related compound (EET) with optimized pharmacokinetic properties. The CEO of the company is Bryan F. Cox. | Health Technology |
- Stock Market
- Insiders
- Bryan Cox